Mr Yazan Masannat, Consultant Oncoplastic Breast Surgeon
Mr Yazan Masannat
Consultant Oncoplastic Breast Surgeon
Mr Yazan Masannat MBBS MRCS(Ed) MRCSI(Dublin) DBRM(UAB) FEBS(Breast Surgery) FRCSEd(Gen Surgery) MD(Leeds)
Consultant Oncoplastic Breast Surgeon
Mr Yazan Masannat
Consultant Oncoplastic Breast Surgeon MBBS MRCS(Ed) MRCSI(Dublin) DBRM(UAB) FEBS(Breast Surgery) FRCSEd(Gen Surgery) MD(Leeds)
Mr Masannat is a recommended Consultant Oncoplastic Breast Surgeon
Areas of expertise
- Breast surgeon
- Breast cancer surgery
- Oncoplastic breast surgery
- Therapeutic mammoplasty
- Breast reconstruction
Recommendations for Mr Masannat
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Make an appointment
Address
-
The London Clinic (Monday: 13:30-17:00, Wednesday: 16:00-18:00, Friday: 13:30-16:00)
Rapid Diagnostic Centre, 142-146 Harley Street, London, W1G 7LD
-
OneWelBeck (Wednesday: 13:30-16:00, Friday: 11:30-13:00)
1 Welbeck Street, Marylebone, London, W1G 0AR
-
The London Breast Clinic (Wednesday: 09:00-13:00, Friday: 09:00-11:00)
108 Harley Street, London, W1G 7ET
-
LIPS Healthcare (Friday: 17:30-20:00)
Battersea Power Station, 1st Floor, Turbine Hall B, London, SW11 8DD
-
Springfield Hospital (Tuesday: 17:00-19:00)
Ramsey Healthcare, Chelmsford, Essex , CM1 7GU
About Mr Yazan Masannat
GMC number: 5207533
Year qualified: 2000
Place of primary qualification: Jordan University of Science & Technology
Initial consultation fee: £325
Follow up consultation fee: £250
Yazan Masannat is a Consultant Oncoplastic Breast Surgeon specialising in the diagnosis and surgical management of the full spectrum of benign and malignant breast disease. He offers advanced breast cancer surgery, oncoplastic breast-conserving procedures (including therapeutic mammoplasty and chest wall perforator flaps), mastectomy, sentinel lymph node biopsy, axillary surgery, and symmetrisation surgery, with a strong focus on achieving optimal oncological and cosmetic outcomes.
He has extensive expertise in immediate and delayed breast reconstruction, offering both implant-based and autologous techniques, breast reduction, and surgery to correct breast asymmetry and working closely with working with some of the best Plastic and Reconstructive Surgeons. He also manages benign breast conditions such as breast lumps, mastalgia, mastitis, and breast abscesses. Mr Masannat runs a rapid-access one-stop breast clinic, providing timely assessment and personalised care for patients presenting with breast symptoms.
Mr Masannat practises in London and Essex. He consults at The London Clinic, 108 Harley Street, OneWelbeck, LIPS at Battersea Power Station in London and Springfield Hospital in Essex. He is known for delivering personalised, evidence-based treatment within a multidisciplinary team setting, ensuring patients receive safe, timely, and compassionate care.
An academic leader and educator, he is a Visiting Associate Professor, an Honorary Senior Clinical Lecturer, and a senior tutor in oncoplastic breast surgery. He has published over 80 peer-reviewed papers in leading surgical and oncology journals and holds several research grants. Beyond his clinical practice, Mr Masannat is the founder and editor of iBreastBook, an international breast surgery education platform and webinar series widely used by surgeons worldwide. He also holds senior professional leadership roles, including serving on the Board of Trustees of the Association of Breast Surgery in the UK, member of the international committee of the American Society of Breast Surgeons (ASBrS) and acting as an examiner for European surgical oncology and breast surgery examinations.
Areas of expertise
- Abscess incision and drainage
- Acellular dermal matrix
- Armpit lump
- Axillary lymph node clearance
- Benign breast disease
- Breast asymmetry after cancer treatment
- Breast cancer
- Breast cancer surgery
- Breast consultation
- Breast lump
- Breast lump excision
- Breast pain management
- Breast reconstruction
- Breast reduction
- Breast surgeon
- Chest wall perforator flap
- Ductal carcinoma in situ (DCIS)
- Early breast cancer diagnosis
- Excision of benign lesions
- Excision of lymph nodes
- Immediate breast reconstruction
- Implant reconstruction
- Malignant breast disease
- Mammoplasty
- Mastalgia (breast pain)
- Mastectomy
- Mastitis
- Neoadjuvant
- Nipple surgery
- Oncoplastic breast conservation surgery
- Oncoplastic breast surgery
- Sentinel lymph node biopsy
- Therapeutic mammoplasty
Professional memberships
.png)
.png)
Articles by Mr Yazan Masannat
The Prognostic Significance of the Serum Inflammatory Marker Ratios, Neutrophil-Lymphocyte, Platelet-Lymphocyte and Monocyte-Lymphocyte in Male Breast Cancer
Adoption of nonwire localisation devices in UK breast units
Abstract P3-12-16: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4 / iBRA-NET, NCT 05559411)
Consensus process to agree upon surgical quality assurance processes within a pragmatic, multicentre randomised clinical trial comparing targeted axillary dissection and axillary node clearance:
MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET/AGO-B-062, NCT 05559411).
Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T
Revisiting surgical margins for invasive breast cancer patients treated with breast conservation therapy - Evidence for adopting a 1 mm negative width
Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer
MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).
Author Correction: Spatial heterogeneity of peri-tumoural lipid composition in postmenopausal patients with oestrogen receptor positive breast cancer
